The article examines the objective, findings, and clinical context described in First IL-17A biologic approved for polymyalgia rheumatica.
Approach:
Approval: The FDA approved secukinumab (Cosentyx) 150 mg for this population, making it the first IL-17A inhibitor approved for PMR in the United States.
Trial: REPLENISH was a randomized, double-blind, placebo-controlled phase 3 trial of 381 adults with PMR and at least one relapse during glucocorticoid tapering. Participants received secukinumab 150 mg, secukinumab 300 mg, or placebo for 52 weeks, alongside a 24-wee…
Primary endpoint: Sustained remission at week 52 required remission by week 12, maintained without a PMR flare or new giant cell arteritis diagnosis requiring rescue treatment.
Key Findings:
Sustained remission occurred in 40.5% of patients receiving secukinumab 150 mg and 20.5% receiving placebo.
Mean adjusted cumulative glucocorticoid dose through week 52 was 1,683.2 mg with secukinumab 150 mg and 2,093 mg with placebo.
Median time to rescue treatment for a PMR flare was 282 days with secukinumab 150 mg and 157 days with placebo.
Serious adverse events occurred in 15.9% of the secukinumab 150 mg group and 14.2% of the placebo group. Hypersensitivity reactions occurred in 14% versus 9%, and urinary tract infections in 13% versus 7%.
A fatal case of cryptococcal meningitis occurred in a secukinumab-treated patient.
Interpretation:
The FDA-approved prescribing information recommends secukinumab 150 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4, then every 4 weeks, in combination with a glucocorticoid taper. It may be continued alone after glucocorticoids are discontinued.
Limitations:
The supplied context reports results for the 150 mg dose versus placebo but does not provide results for the 300 mg dose.
The supplied context does not report additional trial details such as participant demographics or confidence intervals.
Conclusion:
The prescribing information warns of serious infections and inflammatory bowel disease, advises tuberculosis evaluation and age-appropriate vaccinations before treatment, and contraindicates use in patients with serious hypersensitivity to secukinumab or its excipients.